Ultragenyx Pharmaceutical

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RARE and other ETFs, options, and stocks.

About RARE

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. 

CEO
Emil D. Kakkis
CEOEmil D. Kakkis
Employees
1,294
Employees1,294
Headquarters
Novato, California
HeadquartersNovato, California
Founded
2010
Founded2010
Employees
1,294
Employees1,294

RARE Key Statistics

Market cap
2.76B
Market cap2.76B
Price-Earnings ratio
-5.02
Price-Earnings ratio-5.02
Dividend yield
—
Dividend yield—
Average volume
3.05M
Average volume3.05M
High today
$30.17
High today$30.17
Low today
$27.37
Low today$27.37
Open price
$28.56
Open price$28.56
Volume
4.20M
Volume4.20M
52 Week high
$60.37
52 Week high$60.37
52 Week low
$27.37
52 Week low$27.37

RARE News

Benzinga 5h
FDA Delays Approval For Ultragenyx's Gene Therapy, But Not A Dealbreaker, Says Analyst

The U.S. Food and Drug Administration issued on Friday a Complete Response Letter for Ultragenyx Pharmaceutical Inc.’s RARE Biologics License Application (BLA)...

FDA Delays Approval For Ultragenyx's Gene Therapy, But Not A Dealbreaker, Says Analyst
Benzinga 10h
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday. Shares of Ultragenyx Pharmaceutical Inc. RARE fell sharpl...

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga 4d
Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win

Ultragenyx Pharmaceutical Inc. RARE and Mereo BioPharma Group plc MREO stocks are plunging on Thursday. What Happened? The companies on Wednesday announced th...

Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win

Analyst ratings

95%

of 19 ratings
Buy
94.7%
Hold
5.3%
Sell
0%

More RARE News

TipRanks 5d
Ultragenyx Advances Phase 3 Study for UX143 Drug

Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights...

People also own

Based on the portfolios of people who own RARE. This list is generated using Robinhood data, and it’s not a recommendation.
UnitedHealth
Centene
Sarepta Therapeutics
Moderna
Mereo BioPharma Group
Alibaba
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.